Drug Profile


Alternative Names: Flovagatran-sodium; TGN-255

Latest Information Update: 12 Dec 2010

Price : $50

At a glance

  • Originator Trigen Holdings AG
  • Class Anticoagulants; Antithrombotics; Boronic acids; Small molecules
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 07 Dec 2010 Discontinued - Phase-II for Thrombosis in Poland (IV)
  • 07 Dec 2010 Discontinued - Phase-II for Thrombosis in Italy (IV)
  • 07 Dec 2010 Discontinued - Phase-II for Thrombosis in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top